Q-omics provides the consensus-scored PRSS37 profile across patient tissues and cancer cell-line models. PRSS37 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, PRSS37 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, PRSS37 RNA expression shows 14,912 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, KIRC, and THYM as cancer lineages where PRSS37 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRSS37 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRSS37 survival associations across molecular data types. PRSS37 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRSS37 RNA expression–survival associations across cancer types. High PRSS37 expression shows unfavorable associations in KIRP, but favorable associations in HNSC, MESO, LGG, ESCA and BRCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify HNSC as the clearest survival context for PRSS37 RNA expression.
This table summarizes PRSS37 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for PRSS37. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRSS37 shows lower tumor expression in KICH and UCEC and higher tumor expression in KIRC, LIHC, PAAD and ESCA. The KIRC box plot shows higher PRSS37 RNA expression in tumor versus normal tissue (log2 FC = +0.070, t-test p < 0.001).
This table shows molecular features associated with PRSS37 in patient tissues and cancer cell lines. In patient samples, PRSS37 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, PRSS37 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LIVER and SOFT_TISSUE.
